Simethicone

Identification

Summary

Simethicone is an anti-flatulence agent used to relieve pressure, bloating, and symptoms referred to as gas.

Brand Names
Phazyme
Generic Name
Simethicone
DrugBank Accession Number
DB09512
Background

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination.2 It has a favourable safety profile as it is not systemically absorbed.2

Simethicone has been in use since the 1940s1 but was granted FDA approval in 1952.2

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 238.461
Monoisotopic: 238.051288665
Chemical Formula
C6H18O4Si3
Synonyms
  • Simeticona
  • Simeticone
  • Siméticone
  • Simeticonum

Pharmacology

Indication

Simethicone is indicated for the treatment of bloating, pressure, and cramps caused by gas.4 Simethicone is also used as part of bowel preparation for colonoscopies.3

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAbdominal crampsCombination Product in combination with: Alverine (DB01616)•••••••••••••••••••
Used in combination to treatAbdominal painCombination Product in combination with: Alverine (DB01616)•••••••••••••••••••
Used in combination to treatAbdominal painCombination Product in combination with: Loperamide (DB00836)••• •••••••••
Used in combination for symptomatic treatment ofAbdominal distensionCombination Product in combination with: Magnesium hydroxide (DB09104), Magnesium trisilicate (DB09281), Aluminum hydroxide (DB06723)••• •••••••••
Used in combination for symptomatic treatment ofAcid refluxCombination Product in combination with: Magnesium trisilicate (DB09281), Magnesium hydroxide (DB09104), Aluminum hydroxide (DB06723)••• •••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Simethicone decreases the surface tension of gas bubbles in the gastrointestinal tract, facilitating their expulsion.2 It has a short duration of action as it is generally given as needed, and a wide therapeutic index as it is not systemically absorbed.2

Mechanism of action

Simethicone is a surfactant that decreases the surface tension of gas bubbles in the gastrointestinal tract, more easily allowing gas to exit the body.2

Absorption

Simethicone is not systemically absorbed and so these data are not readily available.2

Volume of distribution

Simethicone is not systemically absorbed and so these data are not readily available.2

Protein binding

Simethicone is not systemically absorbed and so these data are not readily available.2

Metabolism

Simethicone is not systemically absorbed and so it is not metabolised by the body.2

Route of elimination

Simethicone is eliminated in the feces.2

Half-life

Simethicone is not systemically absorbed and so these data are not readily available.2

Clearance

Simethicone is not systemically absorbed and so these data are not readily available.2

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Data regarding overdoses with simethicone are rare due to the fact that it is not systemically absorbed.2. In the case of an overdose stop the drug2 and initiate symptomatic and supportive care.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with or without food. Recommendations vary from product to product - consult individual product monographs for additional information.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
air-X 120 TabletTablet120 mgOralIMEKS PHARMA SDN. BHD.2020-09-08Not applicableMalaysia flag
Air-X SF TabletTabletOralIMEKS PHARMA SDN. BHD.2020-09-08Not applicableMalaysia flag
Cancap Simethicone USP 180 Mg Soft CapsulesCapsule180 mgOralCancap Pharmaceutical Ltd2014-01-302018-11-21Canada flag
Disflatyl Tablet 40mgTablet40 mgOralA. MENARINI SINGAPORE PTE. LTD.2020-09-082022-03-03Malaysia flag
Dual-eze Enteric S.C. Tablets 60mgTablet60 mgOralRIGEL PHARMA SDN. BHD.2024-10-01Not applicableMalaysia flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ACED FULL SUSPENSIONSimethicone (400 mg) + Aluminum hydroxide (4 g) + Magnesium hydroxide (4 g)SuspensionOralCOASPHARMA S.A.S.2018-06-12Not applicableColombia flag
ACI-BIOGEL® SUSPENSIONSimethicone (0.4 g) + Aluminum hydroxide (4 g) + Magnesium hydroxide (4 g)SuspensionOralEUROFARMA COLOMBIA S.A.S2006-11-10Not applicableColombia flag
ACITIP SUSPENSIÓNSimethicone (600 mg) + Magaldrate (8000 mg)SuspensionOralLABORATORIOS SIEGFRIED S.A.S.2018-03-262024-01-17Colombia flag
ACITRALSimethicone (20 mg) + Aluminum hydroxide (200 mg) + Magnesium hydroxide (200 mg)Tablet; Tablet, chewableOralInterbat2018-02-132022-10-02Indonesia flag
ACOLIC SYRUPSimethicone (50 mg/5ml) + Dicyclomine hydrochloride (5 mg/5ml)SyrupOralGOLDPLUS UNIVERSAL PTE LTD1998-04-11Not applicableSingapore flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
8050-81-5
InChI Key
AMTWCFIAVKBGOD-UHFFFAOYSA-N
InChI
InChI=1S/C6H18O2Si2.O2Si/c1-7-10(5,6)8-9(2,3)4;1-3-2/h1-6H3;
IUPAC Name
3,3,5,5-tetramethyl-2,4-dioxa-3,5-disilahexane; silanedione
SMILES
O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C

References

General References
  1. KEARNS WM, HEFKE H, MORTON SA: Ditopax; a new excretory urographic medium; a clinical report on 1280 injections. J Urol. 1946 Sep;56:392-8. doi: 10.1016/s0022-5347(17)69822-7. [Article]
  2. Ingold CJ, Akhondi H: Simethicone . [Article]
  3. Tongprasert S, Sobhonslidsuk A, Rattanasiri S: Improving quality of colonoscopy by adding simethicone to sodium phosphate bowel preparation. World J Gastroenterol. 2009 Jun 28;15(24):3032-7. doi: 10.3748/wjg.15.3032. [Article]
  4. FDA Approved Drug Products: Imodium Multi-Symptom Relief (Loperamide HCl, Simethicone) Oral Tablet [Link]
  5. Health Canada Approved Drug Products: Imodium Complete (Loperamide HCl, Simethicone) Oral Chewable Tablets [Link]
PubChem Substance
347910457
ChemSpider
4938661
RxNav
9796
ChEMBL
CHEMBL1200838
Wikipedia
Simeticone

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Not AvailableCompletedNot AvailableBowel Preparation Solutions / Colonoscopy / Colorectal Cancer1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableHealthy Volunteers (HV)1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableInfantile Colics1somestatusstop reasonjust information to hide
Not AvailableCompletedDiagnosticColon Neoplasm / Colorectal Cancer1somestatusstop reasonjust information to hide
Not AvailableCompletedDiagnosticColorectal Neoplasms1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet; tablet, chewableOral
SyrupOral
TabletOral152 mg
TabletOral120 mg
TabletOral300 mg
LiquidOral
SolutionOral
Solution / dropsOral41.2 mg/ml
CapsuleOral
TabletOral200 mg
Powder
TabletOral100.00 mg
Powder, for solutionOral
EmulsionOral62.5 MG/5ML
SyrupOral5 mg/5ml
Capsule, liquid filledOral250 mg
SuspensionOral66.6 mg
Tablet, delayed releaseOral
Tablet, chewableOral46.311 mg
Tablet, chewableBuccal470 mg
TabletOral60 mg
GranuleOral
EmulsionOral
TabletOral40.000 mg
CapsuleOral10 g
CapsuleOral40 mg
EmulsionOral40 mg
Capsule, liquid filledOral125 mg
CapsuleOral166.0 mg
TabletOral150 mg
SuspensionOral1 g
SuspensionAuricular (otic)8.000 g
CapsuleOral
CapsuleOral125.0 mg
CapsuleOral180.0 mg
StripOral62.5 mg
CapsuleOral166 mg
TabletOral50 mg
CapsuleOral140 mg
Tablet, chewableOral50 mg
Tablet, film coatedOral
GelOral
SolutionOral40 mg / 0.6 mL
Tablet, chewableOral
CapsuleOral200 mg
Capsule, liquid filledOral200 mg
Tablet, sugar coatedOral
SuspensionOral40 mg / mL
Tablet, chewableOral105 mg
SuspensionOral41.2 mg
TabletOral0.050 g
SuspensionOral10.000 g
Powder, for suspensionOral
TabletOral40.00 mg
LiquidOral20 mg / 0.3 mL
TabletOral200.000 mg
Capsule, liquid filledOral
Capsule, coatedOral
SuspensionOral40 mg/5ml
Solution / dropsOral
Tablet, coatedOral
SuspensionOral400 mg/5ml
Solution / dropsOral6.66 %
Solution / dropsOral66.6 mg
TabletOral40 MG
Tablet, chewableOral40 MG
SolutionOral40 mg/0.6ml
Solution / dropsOral40 mg / mL
TabletOral180 mg
CapsuleOral95 mg
EmulsionOral62.5 mg / 5 mL
GelOral30 %
TabletOral
SyrupOral50 MG/5ML
SyrupOral6.67 g
EmulsionOral100 mg/ml
SuspensionOral69.19 mg/ml
Tablet, chewableOral69.19 mg/ml
Solution / dropsOral69.19 mg/ml
SuspensionOral30 ml
Granule, effervescentOral
TabletOral125 MG
SuspensionOral66 mg
Tablet, chewableOral125 mg
Tablet, chewableBuccal125 mg
TabletOral
SuspensionOral
Tablet, chewableOral
EmulsionOral80 mg/ml
EmulsionOral
Tablet, chewableOral85 mg
Tablet, chewableOral180 mg
Tablet, chewableOral80 MG
Tablet, chewableBuccal100 mg
Tablet, chewableOral42 MG
Solution / dropsOral66.6 MG/ML
Tablet, chewableOral120 MG
Suspension / dropsOral
Tablet, film coated
SuspensionOral57.97 g
SuspensionOral100.00 mg
SuspensionOral
SuspensionOral41.2 mg/mL
TabletOral250 mg
SuspensionOral40 mg/1ml
SuspensionOral67 mg/1ml
Tablet
EmulsionOral40 mg/0.6ml
CapsuleOral125 mg
CapsuleOral180 mg
SuspensionOral120 mg/15ml
CapsuleOral150 mg
Solution
TabletOral100 mg
SuspensionOral40 mg/0.6ml
TabletOral80 mg
Suspension
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6103260No2000-08-152017-07-17US flag

Properties

State
Liquid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.71 mg/mLALOGPS
logP2.6ALOGPS
logP1.76Chemaxon
logS-2ALOGPS
pKa (Strongest Basic)-3.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area18.46 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity37.63 m3·mol-1Chemaxon
Polarizability18.48 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at November 30, 2015 19:10 / Updated at October 03, 2024 04:54